FEDERAL COURT OF AUSTRALIA
Pharmacia Italia SpA v Mayne Pharma Pty Ltd [2006] FCA 305
PATENTS – infringement of pharmaceutical patent – existing injunction restrains respondents until conclusion of initial term of patent – extension of term of pharmaceutical patent granted prior to infringement proceedings – whether injunction restraining respondents should also apply to period of extension – basis upon which patent capable of extension – whether claim in respect of pharmaceutical substance per se – whether references in patent specifications to elements of “process” or “method” prevent claim from being a claim in respect of a pharmaceutical substance per se – rectification of Register – whether s 192 of Patents Act 1990 (Cth) allows only for the correction of clerical and like errors
ADMINISTRATIVE LAW – application for judicial review – decision by Commissioner of Patents to accept an application, and to fail to refuse to accept an application, for extension of term of patent – decision by Commissioner of Patents to grant an extension of term of patent – whether compound consisting of both therapeutic substance and inert substances is a “pharmaceutical substance” – whether patent for a pharmaceutical substance per se – effect of delay in bringing application for review
WORDS AND PHRASES – “pharmaceutical substance per se”, “pharmaceutical substance”
Administrative Decisions (Judicial Review) Act 1977 (Cth) ss 5 and 11
Judiciary Act 1903 (Cth) s 39B
Patents Act 1990 (Cth) ss 70, 78, 192
Patents Regulations 1991 (Cth) r 5Boehringer Ingelheim International GmbH v Commissioner of Patents (2001) 112 FCR 595 applied
Boehringer Ingelheim International v Commissioner of Patents (2001) AIPC ¶91-670 followed
Lockwood Security Products Pty Ltd v Doric Products Pty Limited (2004) 217 CLR 274 cited
Pharmacia Italia SpA v Mayne Pharma Pty Ltd (2005) 222 ALR 552 discussed
Prejay Holdings Ltd v Commissioner of Patents (2003) 57 IPR 424 referred to
Rehm Pty Ltd v Websters Security Systems (International) Pty Ltd (1988) 81 ALR 79 citedPHARMACIA ITALIA SpA and PFIZER (PERTH) PTY LIMITED (FORMERLY PHARMACIA (PERTH) PTY LIMITED) v MAYNE PHARMA PTY LTD, F H FAULDING & CO LTD and FAULDING HEALTHCARE PTY LTD
VID 439 OF 2003
INTERPHARMA PTY LTD v THE COMMISSIONER OF PATENTS and PHARMACIA ITALIA SpA
VID 1274 OF 2005
WEINBERG J
29 MARCH 2006
MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 439 OF 2003
BETWEEN:
PHARMACIA ITALIA SpA
FIRST APPLICANTPFIZER (PERTH) PTY LIMITED (FORMERLY PHARMACIA (PERTH) PTY LIMITED)
SECOND APPLICANTAND:
MAYNE PHARMA PTY LTD
FIRST RESPONDENTF H FAULDING & CO LTD
SECOND RESPONDENTFAULDING HEALTHCARE PTY LTD
THIRD RESPONDENTJUDGE:
WEINBERG J
DATE OF ORDER:
29 MARCH 2006
WHERE MADE:
MELBOURNE
THE COURT ORDERS THAT:
1.The parties file proposed minutes of orders in accordance with these reasons for judgment, and any other orders or directions appropriate for the future disposition of the matter, on or before 19 April 2006.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE…
Keep reading for free
Create a free CaseChat account to read Pharmacia Italia SpA v Mayne Pharma Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] FCA 305
- Decision Date
CaseChat Overview and Summary
The court's reasoning focused on the interpretation of the patent claims, particularly the phrase "not been reconstituted from a lyophilizate" in claim 1. The court considered the specific language and technical details of the patent to determine the scope of protection granted. Additionally, the court examined whether the use of sodium hydroxide, in addition to hydrochloric acid, to adjust the pH of the solution, fell outside the scope of the patent's claims. The court's decision ultimately hinged on the precise interpretation of the patent claims and whether Mayne Pharma's actions fell within or outside these claims.
The court dismissed the application for review brought by Interpharma, a related entity to Mayne Pharma. The dismissal was based on the finding that Interpharma had not acted within a reasonable time to challenge the extension of the patent term. The court found that Interpharma's delay in filing the application for review was unreasonable, particularly given their awareness of the potential infringement and the patent extension decision. Consequently, the court ruled that the application for review was not made within a reasonable time, leading to its dismissal. The court also noted that the substantive merits of Interpharma's application were weak, and the delay further undermined the case for granting relief.
Orders
Orders of the court
1. The parties file proposed minutes of orders in accordance with these reasons for judgment, and any other orders or directions appropriate for the future disposition of the matter, on or before 19 April 2006.
1. The application be dismissed.
2. The applicant pay the second respondent’s costs
Background
Background to the litigation
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: WEINBERG J
Under the Administrative Decisions (Judicial Review) Act 1977, the Court has the discretion to refuse to entertain an application for an order of review if it is not made within a reasonable time after the decision was made. The Court must consider the time when the applicant became aware of the decision and any other relevant matters. The Court found that Interpharma's delay in filing the application was not adequately explained and amounted to an unreasonable delay. Interpharma had been aware of the Commissioner's decision to extend the patent term since 6 April 2002, but did not file its application for review until 11 October 2005. The Court held that Interpharma's assumption that the processes by which EBEWE Pharma proposed to manufacture doxorubicin EBEWE and epirubicin EBEWE for the Australian market did not come within the claims specified in the Patent was not a sufficient justification for the delay. Furthermore, the Court held that s 192 of the Patents Act, which allows for rectification of the Register, did not provide a basis for granting relief in this case, as the need to ensure that the Register was properly maintained did not justify the delay. The Court also held that the Commissioner's decision to extend the patent term was justified and that Interpharma did not have standing to challenge this decision. The Court found that the Commissioner had acted within his statutory powers and that there was no evidence to suggest that the decision was flawed or unjust. The Court dismissed the application for review and ordered that the applicant pay the second respondent's costs.